Silo Wellness Executes Definitive Agreement to Acquire Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio
September 27, 2022
Ryan Allway September 27th, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – September 27, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) (“Silo Wellness” or the “Company”), a leading global psychedelics company, and Dyscovry Science Ltd. (“Dyscovry”), a Toronto-based biotechnology company focused on biosynthetic manufacturing of... Read more
Ryan Allway May 31st, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – May 31, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that it has executed a nonbinding letter of intent to... Read more
